The FDA rejected pSivida Corp.’s (NSDQ:PSDV) and Alimera Sciences Inc.’s (NSDQ:ALIM) resubmitted new drug application for the Iluvien eye treatment, citing a lack of safety and efficacy data.
Iluvien is designed to deliver sustained, low doses of flucocinolone acetonide to the retina at the rear of the eyeball in patients with diabetic macular edema.